MADRID — Akeso on Sunday spelled out by how much its Summit Therapeutics-partnered PD-1xVEGF bispecific improved survival in a late-stage, China-only biliary tract cancer study …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.